Charting the Global Biosimilar Pipeline 2018: Biosimilars in Development for a Range of Therapy Areas from Cancer and Diabetes to Ophthalmology and Respiratory - ResearchAndMarkets.com

DUBLIN--()--The "Charting the Global Biosimilar pipeline" report has been added to ResearchAndMarkets.com's offering.

There are multiple biosimilars in development for a range of therapy areas from cancer and diabetes to ophthalmology and respiratory. High-value mAbs such as Roche's Avastin (bevacizumab), Abbvie's Humira (adalimumab) and Janssen/Merck & Co's Remicade (infliximab) are being targeted by multiple biosimilar developers. But which companies are leading the market? What products are being targeted? Where is development geographically concentrated? What licensing and collaboration opportunities are there?

What is the true potential of the much hyped biosimilar market?

At present there are 260 biosimilar products which are approved in at least one market - and many of those are first generation products such as hormones. The future, however, is looking more interesting with 188 biosimilars in development, 61 of which are in Phase III trials.

The number of high value mAbs for a wide range of conditions has increased. Development continues to be concentrated in countries such as India, China, Bangladesh, Iran and South Korea. In contrast, high development cost, originator defence strategies and more stringent regulatory regimes are pegging back development interest in the US and Europe.

In the US there are 6 companies with 8 biosimilars registered . The sector is dominated by originator companies such as Pfizer, Amgen and Merck & Co. Europe is scarcely better with 9 companies and 13 biosimilars registered. The global biosimilar market is maturing both in its scope and ambitions.

Key Topics Covered:

1. Report methodology and objectives

2. Overview

  • Biosimilars by therapy area
  • Biosimilars by product class
  • Most popular/bestselling biosimilar product candidates
  • Biosimilars by development stage
  • Leading biosimilar companies

3. Biosimilar pipeline by product

  • Abatacept
  • Abciximab
  • Adalimumab
  • Aflibercept
  • Anakinra
  • Bevacizumab
  • Certolizumab pegol
  • Cetuximab
  • Daclizumab
  • Darbepoetin alfa
  • Denosumab
  • Eculizumab
  • Enoxaparin
  • Epoetin alfa
  • Etanercept
  • Filgrastim
  • Follitropin alfa
  • Infliximab
  • Insulin aspart
  • Insulin glargine
  • Insulin (human)
  • Insulin lispro
  • Interferon alfa-2A
  • Interferon alfa-2B
  • Interferon beta-1A
  • Interferon beta-1B
  • Interleukin-2
  • Interleukin-11
  • Omalizumab
  • Palivizumab
  • Pegfilgrastim
  • Peginterferon alfa-2A
  • Peginterferon alfa-2B
  • Pertuzumab
  • Ranibizumab

4. Biosimilar pipelines by company

  • Accord Healthcare
  • Adello Biologics
  • Alteogen
  • Centus Biotherapeutics
  • Cipla
  • Coherus Biosciences
  • Dem Ila
  • Dr Reddy's
  • Epirus Biopharmaceuticals
  • Finox Biotech
  • Formycon AG
  • Fresenius
  • Fuji Pharma
  • Fujifilm Kyowa Kirin Biologics
  • Glenmark
  • Lilly
  • Mabion
  • mAbxience
  • Merck & Co
  • Mochida
  • Momenta
  • Nichi-IkoProduct and pipeline status
  • Nippon Kayaku
  • Pfenex
  • Pfizer
  • Rovi
  • Samsung Bioepsis
  • Sandoz (Novartis)
  • Sanofi
  • Stada Arzneimittel
  • Techdow Europe AB
  • Teva
  • Torrent Pharmaceuticals
  • USV
  • Wockhardt

For more information about this report visit https://www.researchandmarkets.com/research/gd8qdk/charting_the?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biosimilars and Biosuperiors

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Biosimilars and Biosuperiors